Metformin for Neurodegeneration

Migration, Crosslink

📖

Metformin for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-metformin-neurodegener

📖 Wiki Page

therapeutic769 wordssynced 2026-04-02

Metformin for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metformin for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Participants</td>
</tr>
<tr>
<td class="label">Retrospective (2020)</td>
<td>9,000+ T2D patients</td>
</tr>
<tr>
<td class="label">Phase II Trial (2021)</td>
<td>120 AD patients</td>
</tr>
<tr>
<td class="label">Observational (2022)</td>
<td>5,000 diabetic patients</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Participants</td>
</tr>
<tr>
<td class="label">Retrospective (2019)</td>
<td>2,000 PD patients</td>
</tr>
<tr>
<td class="label">Phase II Trial (2021)</td>
<td>80 PD patients</td>
</tr>
<tr>
<td class="label">Preclinical (2020)</td>
<td>Mouse models</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Metformin + GLP-1 agonists</td>
<td>Enhanced neuroprotection</td>
</tr>
<tr>
<td class="label">Metformin + Lifestyle interventions</td>
<td>Synergistic cognitive benefit</td>
</tr>
<tr>
<td class="label">Metformin + Existing AD drugs</td>
<td>Additive effects</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Effect of Metformin</td>
</tr>
<tr>
<td class="label">Aβ42 (CSF)</td>
<td>Reduced in some studies</td>
</tr>
<tr>
<td class="label">Total [tau](/proteins/tau) (CSF)</td>
<td>May increase</td>
</tr>
<tr>
<td cl

...

Metformin for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metformin for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Participants</td>
</tr>
<tr>
<td class="label">Retrospective (2020)</td>
<td>9,000+ T2D patients</td>
</tr>
<tr>
<td class="label">Phase II Trial (2021)</td>
<td>120 AD patients</td>
</tr>
<tr>
<td class="label">Observational (2022)</td>
<td>5,000 diabetic patients</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Participants</td>
</tr>
<tr>
<td class="label">Retrospective (2019)</td>
<td>2,000 PD patients</td>
</tr>
<tr>
<td class="label">Phase II Trial (2021)</td>
<td>80 PD patients</td>
</tr>
<tr>
<td class="label">Preclinical (2020)</td>
<td>Mouse models</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Metformin + GLP-1 agonists</td>
<td>Enhanced neuroprotection</td>
</tr>
<tr>
<td class="label">Metformin + Lifestyle interventions</td>
<td>Synergistic cognitive benefit</td>
</tr>
<tr>
<td class="label">Metformin + Existing AD drugs</td>
<td>Additive effects</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Effect of Metformin</td>
</tr>
<tr>
<td class="label">Aβ42 (CSF)</td>
<td>Reduced in some studies</td>
</tr>
<tr>
<td class="label">Total [tau](/proteins/tau) (CSF)</td>
<td>May increase</td>
</tr>
<tr>
<td class="label">p-[tau](/proteins/tau) (CSF)</td>
<td>Stabilization observed</td>
</tr>
<tr>
<td class="label">Inflammatory markers</td>
<td>Reduced (IL-6, TNF-α)</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Increased peripheral levels</td>
</tr>
</table>

Metformin For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Metformin is a widely prescribed antidiabetic medication that has shown neuroprotective potential in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. Its mechanisms include AMPK activation, autophagy enhancement, mitochondrial function improvement, and reduction of neuroinflammation. [@metformin2014]

Mechanism of Action

Primary Mechanisms

AMPK Activation: Metformin activates AMP-activated protein kinase (AMPK) through inhibition of mitochondrial complex I, leading to:

Enhanced autophagy and lysosomal function
Improved mitochondrial biogenesis
Reduced mTORC1 signaling
Cellular energy homeostasis

Mitochondrial Function

Increases mitochondrial DNA copy number
Improves Complex I activity
Reduces [ROS](/entities/reactive-oxygen-species) production
Enhances ATP production

[Autophagy](/entities/autophagy) Enhancement

Activates ULK1 kinase complex
Promotes clearance of protein aggregates ([Aβ](/proteins/amyloid-beta), α-syn, tau)
Improves lysosomal function

Neuroinflammation Reduction

Inhibits [NLRP3](/entities/nlrp3-inflammasome) inflammasome
Reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
Modifies microglial activation

Insulin Signaling Improvement

Reduces peripheral insulin resistance
Improves brain insulin sensitivity
Linked to "Type 3 Diabetes" hypothesis of AD

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Animal models show motor neuron protection
Huntington's Disease (HD): Improved motor function in mouse models
Multiple Sclerosis (MS): Reduced relapse rates in pilot studies

Therapeutic Considerations

Dosing

Standard diabetic dose: 500-2000 mg/day
Neuroprotective potential: May require higher doses
Extended-release formulation: Better GI tolerance

Combination Therapies

Safety Profile

Generally well-tolerated
Common: GI upset (nausea, diarrhea)
Rare: B12 deficiency, lactic acidosis
Contraindicated: Severe renal impairment

Biomarker Studies

Clinical Trials

Active/Recruiting Trials

NCT05002214: Metformin for Early AD (Phase II)
NCT04616348: Metformin in PD with Diabetes (Phase III)
NCT05367245: Metformin for MCI (Phase II)

Completed Trials

NCT00620121: Safety in AD patients
NCT03482682: Cognitive effects in T2D

Background

The study of Metformin For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov - Metformin Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative+disorders&intr=metformin)
[ADA Standards of Care - Metformin](https://diabetes.org/)

References

[1] Zhou G, et al, Metformin induces autophagy and lysosomal function (2019)

[2] Foretz M, et al, Metformin: mode of action and clinical implications (2014)

[3] Lin YT, et al, Metformin reduces risk of Alzheimer's disease in type 2 diabetic patients (2020)

[4] Papanas N, et al, Metformin and neurodegeneration: a systematic review (2021)

[5] Katz L, et al, Metformin activates AMPK to promote autophagy and protect against neuronal death (2022)

[6] Athanasopoulos P, et al, Neuroprotective effects of metformin in Parkinson's disease: mechanisms (2020)

[7] Wang Y, et al, Metformin improves mitochondrial function in Alzheimer's disease models (2022)

[8] Isoda K, et al, Metformin prevents dopaminergic neuron death in Parkinson's disease models (2021)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-metformin-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-metformin-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e50e42c288ee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-metformin-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

728

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Metformin for Neurodegeneration

Metformin for Neurodegeneration

Introduction

Metformin for Neurodegeneration

Introduction

Overview

Mechanism of Action

Primary Mechanisms

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Therapeutic Considerations

Dosing

Combination Therapies

Safety Profile

Biomarker Studies

Clinical Trials

Active/Recruiting Trials

Completed Trials

Background

Allen Brain Atlas Resources

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Metformin for Neurodegeneration

Metformin for Neurodegeneration

Introduction

Metformin for Neurodegeneration

Introduction

Overview

Mechanism of Action

Primary Mechanisms

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Therapeutic Considerations

Dosing

Combination Therapies

Safety Profile

Biomarker Studies

Clinical Trials

Active/Recruiting Trials

Completed Trials

Background

Allen Brain Atlas Resources

See Also

External Links

References

Related Hypotheses

💬 Discussion